
BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors. Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME Li Li		POSITION TITLE	
eRA COMMONS USER NAME (credential, e.g., agency login) LILI978		Assistant Professor University of Alabama at Birmingham	
EDUCATION/TRAINING (<i>Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable.</i>)			
INSTITUTION AND LOCATION	DEGREE (if applicable)	MM/YY	FIELD OF STUDY
Hubei Medical University, Wuhan, P.R. China	M.D.	1990-1998	Medicine
Georgia State University, Atlanta	Ph.D.	2000-2004	Physiology
University of Alabama at Birmingham (UAB)	Resident	2009-2013	Psychiatry

A. Personal Statement

Dr. Li has been investigating mechanisms that modulate glucose homeostasis since she was a Ph.D student in 2000. She has used electrophysiological, and cellular and molecular approaches to investigate how genetic and environmental factors regulate glucose homeostasis and insulin sensitivity. In the past few years, she used several animal models including trauma and hemorrhage, and learned-helplessness mouse models to understand how acute physiological and psychosocial stresses impair glucose homeostasis and induce insulin resistance. In the past 18 months, Dr. Li has been working on the impacts of early life stress on the development of obesity. Dr. Li has made a number of important original contributions in understanding the mechanisms in these two field and has more than 20 peer-reviewed publications reflecting her research achievements. She is now expanding these studies into human studies. The objective of this study is to determine the impacts of psychological stress including early life stress (with and without depression) and acute stress on obesity and diabetes risk by examining the roles of immune system and the HPA axis. The preliminary data are very promising, and this proposal will lay a critical foundation for a NIH grant application.

B. Positions and Honors

Positions and Employment

1998-2000	Instructor, Hubei Medical University, Wuhan, P.R.China
2005-2008	Research Associate, Department of Pathology, UAB
7/2013-present	Assistant Professor, Department of Psychiatry, UAB
7/2013-present	Associate Scientist, Nutrition Obesity Research Center, UAB
8/2013-present	Associate Scientist, Center for Exercise Medicine, UAB

Professional Memberships

2009-present	Member, American Psychiatric Association (APA)
2009-present	Member, Alabama Psychiatric Physicians Association (APPA)
2009-present	Licensee, State of Alabama Medical Licensure Commission
2010-present	Federal DEA

Honors and Awards (U.S)

Graduate

2000-2004	Outstanding Graduate Scholarship Award, Georgia State University, Atlanta, GA
2004	William G. Nolan Memorial Award, Georgia State University, Atlanta, GA

Postdoc

2007 Travel Award, Cystic Fibrosis Foundation
2009 Travel Award, Diabetes Research Training Center, UAB

Residency

2010 Nominee for the best PGY-1 for the Argus Awards, University of Alabama, School of Medicine, AL
2010 Invited guest for American College of Neuropsychopharmacology, Miami, FL
2011 Selectee, Clinical and Translational Science training program, UAB
2011 Resident of Month in the Department of Psychiatry, UAB
2011 Travel award, Clinical and Translational Science training, UAB
2012 1st place research poster award from APPA
2012 1st place research poster award from Department of Psychiatry, UAB
2012 PRITE exam academic excellence award (for the best class performance in psychiatry), UAB
2012 Psychodynamic competence test academic excellence award, UAB
2012 Travel award, American College of Neuropsychopharmacology, Hollywood, FL
2013 1st place research poster award from APPA, AL
2013 3rd place research poster award from the Department of Psychiatry, UAB
2013 Travel award, Society of Biological Psychiatry, San Francisco, CA
2013 Selectee, Research Colloquium for Junior Investigator, American Psychiatric Association, San Francisco, CA

C. Selected Peer-reviewed Publications (from over 27 publications)

1. Li, L., Li, X., Zhou, W and Messina, JL. (2013) Tissue specific effects of psychological stress on the development of acute insulin resistance. *Journal of Endocrinology*, 217:175-184
2. Corrick, R., Li, L., Franklin, JL and Messina, JL. (2013) Hepatic growth hormone resistance following acute injury. *Endocrinology*, 154:1577-1588
3. Xi, H., Liu, J., Li, L and Wan, J (2013) Relationship of the E23K and I337V polymorphisms in the Kir6.2 subunit of the KATP channel with patients with dilated cardiomyopathy. *Genetics and Molecular Research*, 12:4383-4392

(Note: Break in publication record reflects time spent in residency training from 2009-2013)

4. Li, L and Messina, JL. (2009) Acute insulin resistance following injury (invited review). *Trends in Endocrinology and Metabolism*, 20:429-435
5. Li, L., Thompson, LH., Zhao, L and Messina, JL. (2009) Differential molecular mechanisms for hepatic and skeletal muscle acute insulin resistance following hemorrhage and trauma. *Endocrinology*, 150:24-32
6. Falany, CN., He, D., Li, L., Falany, JL., Wilbon, TW., Kocarek, T and Runge-Morris, M. (2009) Regulation of hepatic sulfotransferase (SULT) 1E1 expression and effects on estrogenic activity in cystic fibrosis. *Journal of Steroid Biochemistry and Molecular Biology*, 114:113-119
7. Li, L and Falany, CN. (2009) Role of sulfation in the dysregulation of growth hormone signaling in cystic fibrosis mice. *Steroid*, 74:20-29
8. He, D., Wilborn, TA., Li, L and Falany CN. (2008) Repression of CFTR activity in human MMNK-1 cholangiocytes induces sulfatransferase 1E1 expression in co-cultured HepG2 hepatocytes. *Biochimica et Biophysica Acta*, 1783:1391-1397
9. Li, L and Falany, CN. (2007) Elevation of Hepatic SULT1E1 expression in mouse models of cystic fibrosis alters the regulation of estrogen responsive proteins. *Journal of Cystic Fibrosis*, 6:23-30

10. Li, L., Cui, N., Wang, X., Shi, Y., Shi, W and Jiang, C. (2006) Dysregulation of Kir6.2 channel with R371H and P266T mutations associated with sudden cardiac death following acute myocardial infarction. *Physiological Genomics*, 25:105-115
11. Li, L., Shi, Y., Wang, X., Shi, W and Jiang, C. (2005) Single-nucleotide polymorphism in KATP channels: muscular impact on type 2 diabetes. *Diabetes*, 54: 1592-1597
12. Li, L., Rojas, A., Wu, J and Jiang, C. (2004) Disruption of glucose sensing and insulin secretion by ribozyme Kir6.2-gene targeting in insulin-secreting cells. *Endocrinology*, 145:4408-4414
13. Li, L., Wu, J and Jiang, C. (2003) Differential expression of Kir6.1 and SUR2B mRNA in vasculatures of various tissues in rats. *Journal of Membrane Biology*, 196:1-9
14. Wang, X., Wu, J., Li, L, Chen, F., Wang, R and Jiang, C. (2003) Hypercapnic acidosis activates KATP channels in vascular smooth muscles. *Circulation Research*, 92: 1225-1232
15. Cui, N., Wu, J., Xu, H., Wang, X., Rojas, A., Piao, H., Mao, J., Abdulkadir, L., Li, L and Jiang, C. (2003) Athreonine residue (Thr71) plays a critical role in the gating Kir6.2 channel by intracellular ATP and pH. *Journal of Membrane Biology*, 192:111-122

D. Grant Support

Active

- | | |
|----------------|---|
| 7/2013-6/2016 | Start-up Research Funds as an Assistant Professor, Department of Psychiatry, UAB
Role: PI; Mentor: Dr. Richard C. Shelton |
| 7/2013-6/2015 | Pilot and Feasibility Award, Nutrition Obesity Research Center, UAB
Role: PI; Mentors: Drs. Richard C. Shelton/Barbara Gower |
| 1/2014-12/2015 | Young Investigator Award, Brain and Behavioral Research Foundation
Role: PI; Mentors: Drs. Richard C. Shelton/Lori McMahan |
| 1/2011-12/2013 | Junior Investigator Fund, Chinese Nature and Science Foundation, China
Role: co-PI, PI: Jun Wan |

Completed

- | | |
|----------------|--|
| 10/2006-9/2008 | Pilot Study Research Program, Cystic Fibrosis Research, Inc.
Role: co-PI, PI: Charles N. Falany |
| 1/2009-12/2009 | Young Investigator Fund, Chinese Nature and Science Foundation, China
Role: co-PI, PI: Jun Wan |
| 1/2011-6/2013 | Internal Grant, Department of Psychiatry, UAB
Role: PI |

E. Clinical Trial

1. Novartis CAGO178C2302: "An 8-week, randomized, double-blind, placebo-controlled, parallel-group, multi-center study of the efficacy and safety of agomelatine 0.5 mg and 1 mg sublingual tablets administered once daily in patients with Major Depressive Disorder (MDD)" 2011-2012
2. Novartis CAGO178C2399: "A 52-week, multi-center, open-label study of the safety and tolerability of agomelatine sublingual tablets in patients with Major Depressive Disorder (MDD)" 2011-2012
3. Otsuka 331-08-212: "A Phase 2, Multicenter, Open-label Study to Assess the Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adult Patients with Major Depressive Disorder" 2011-2012

4. Otsuka 31-08-250: "A 52-week, Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients with Bipolar I Disorder" 2012-Present
5. Takeda 375SL-201: "A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) 0.1, 0.4, and 0.8 mg as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated with Bipolar I Disorder in Adult Subjects" 2012-Present
6. Takeda 375SL-203: "A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375SL 0.1, 0.4, and 0.8 mg as an Adjunctive Therapy to Treatment-as-Usual in the Maintenance Treatment of Bipolar 1 Disorder in Adult Subjects" 2012-Present
7. "Comparative Effectiveness of a Second Generation Antipsychotic Mood Stabilizer and a Classic Mood Stabilizer for Bipolar Depression" 2012-2013